Education
About Us
Working with TipRanks
Follow Us
Rocket Pharma (DE:9IP1)
:9IP1
9IP1 Analyst Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
9IP1 Stock 12 Month Forecast
Average Price Target
€36.61
▲(320.28% Upside)
| Highest Price Target€51.82 | Average Price Target€36.61 | Lowest Price Target€14.13 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Chardan Capital
Reiterated
02/28/25
Cantor Fitzgerald
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/28/25
J.P. Morgan
Reiterated
02/28/25
William Blair
Reiterated
02/28/25
Goldman Sachs
Reiterated
02/28/25
Canaccord Genuity
Reiterated
02/28/25
LifeSci Capital
Reiterated
02/28/25
Morgan Stanley
Reiterated
02/28/25
TD Cowen
Reiterated
02/28/25
Needham
€39.57
Buy
354.36%
Upside
Reiterated
02/28/25
Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability
Wedbush
€30.15
Buy
246.18%
Upside
Reiterated
02/28/25
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target
Leerink Partners
€37.69→€36.75
Buy
321.91%
Upside
Reiterated
02/27/25
Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
Evercore ISI
€45.23→€30.15
Buy
246.18%
Upside
Reiterated
12/20/24
Evercore ISI Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Jefferies
€27.33
Buy
213.72%
Upside
Initiated
12/18/24
Rocket Pharmaceuticals initiated with a Buy at JefferiesRocket Pharmaceuticals initiated with a Buy at Jefferies
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Chardan Capital
Reiterated
02/28/25
Cantor Fitzgerald
Reiterated
02/28/25
Bank of America Securities
Reiterated
02/28/25
J.P. Morgan
Reiterated
02/28/25
William Blair
Reiterated
02/28/25
Goldman Sachs
Reiterated
02/28/25
Canaccord Genuity
Reiterated
02/28/25
LifeSci Capital
Reiterated
02/28/25
Morgan Stanley
Reiterated
02/28/25
TD Cowen
Reiterated
02/28/25
Needham
€39.57
Buy
354.36%
Upside
Reiterated
02/28/25
Positive Outlook for Rocket Pharmaceuticals Amidst Regulatory Progress and Financial Stability
Wedbush
€30.15
Buy
246.18%
Upside
Reiterated
02/28/25
Promising Outlook for Rocket Pharmaceuticals: Buy Rating Reiterated with $32 Price Target
Leerink Partners
€37.69→€36.75
Buy
321.91%
Upside
Reiterated
02/27/25
Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
Evercore ISI
€45.23→€30.15
Buy
246.18%
Upside
Reiterated
12/20/24
Evercore ISI Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
Jefferies
€27.33
Buy
213.72%
Upside
Initiated
12/18/24
Rocket Pharmaceuticals initiated with a Buy at JefferiesRocket Pharmaceuticals initiated with a Buy at Jefferies
Best Analysts Covering Rocket Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy DE:9IP1 and Sell After:
1 Month
xxx
Success Rate
14/23 ratings generated profit
Average Return
+9.05%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.87% of your transactions generating a profit, with an average return of +9.05% per trade.
3 Months
xxx
Success Rate
14/23 ratings generated profit
Average Return
+20.03%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +20.03% per trade.
1 Year
Success Rate
8/13 ratings generated profit
Average Return
+9.98%
reiterated a buy rating 4 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +9.98% per trade.
2 Years
xxx
Success Rate
6/23 ratings generated profit
Average Return
-13.47%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 26.09% of your transactions generating a profit, with an average return of -13.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
9IP1 Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
13
23
22
25
18
Buy
6
7
5
5
2
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
31
28
31
21
Each month's total comprises the sum of three months' worth of ratings.
9IP1 Financial Forecast
9IP1 Stock Forecast FAQ
What is DE:9IP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Rocket Pharma’s 12-month average price target is €36.61.
What is DE:9IP1’s upside potential, based on the analysts’ average price target?
Rocket Pharma has 320.28% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rocket Pharma a Buy, Sell or Hold?
Rocket Pharma has a consensus rating of Strong Buy, which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Rocket Pharma’s share price target?
The average share price target for Rocket Pharma is €36.61. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €51.82 ,and the lowest forecast is €14.13. The average share price target represents 320.28% Increase from the current price of €8.71.
The highest analyst share price target is €51.82 ,and the lowest forecast is €14.13. The average share price target represents 320.28% Increase from the current price of €8.71.
What do analysts say about Rocket Pharma?
Rocket Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of Rocket Pharma?
To buy shares of DE:9IP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.